Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.78 | N/A | -2.23% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.78 | N/A | -2.23% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about near-term performance while highlighting their commitment to future growth. They are focused on technology advancements and market positioning.
Management acknowledged challenges in achieving profitability.
They emphasized ongoing investments in technology and growth.
There was a focus on long-term strategy despite current setbacks.
Twist Bioscience's earnings report indicates ongoing challenges, particularly in achieving profitability, which contributed to a 5.15% drop in stock price. Investors may be concerned about the lack of revenue data and the absence of guidance, which adds uncertainty to the company's future performance. The management's defensive tone suggests they are aware of the hurdles ahead but remain focused on long-term growth strategies.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SUNCOR ENERGY INC NE
May 3, 2021